AstraZeneca plc (AZN) Rating Reiterated by J P Morgan Chase & Co
AstraZeneca plc (LON:AZN)‘s stock had its “neutral” rating reaffirmed by J P Morgan Chase & Co in a research note issued to investors on Friday.
Other equities research analysts have also recently issued reports about the company. BNP Paribas reiterated a “neutral” rating and issued a GBX 5,300 ($69.21) price objective on shares of AstraZeneca plc in a report on Monday, April 3rd. UBS AG set a GBX 5,150 ($67.25) price objective on AstraZeneca plc and gave the stock a “neutral” rating in a report on Wednesday, April 5th. HSBC Holdings plc restated a “reduce” rating and set a GBX 4,200 ($54.84) target price on shares of AstraZeneca plc in a report on Friday, May 5th. Shore Capital restated a “sell” rating on shares of AstraZeneca plc in a report on Wednesday, May 10th. Finally, Berenberg Bank boosted their target price on AstraZeneca plc from GBX 5,670 ($74.04) to GBX 5,850 ($76.39) and gave the stock a “buy” rating in a report on Wednesday, May 17th. Three investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and nine have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of GBX 5,251.80 ($68.58).
Shares of AstraZeneca plc (LON AZN) traded up 0.57% during trading on Friday, reaching GBX 5152.00. The company had a trading volume of 1,577,047 shares. AstraZeneca plc has a 52 week low of GBX 3,996.00 and a 52 week high of GBX 5,520.00. The company’s market capitalization is GBX 65.22 billion. The stock’s 50-day moving average price is GBX 5,235.89 and its 200-day moving average price is GBX 4,847.81.
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.